Okami Medical

What Okami Medical does

Okami Medical, Inc. is a privately-held medical device company headquartered in Aliso Viejo, California, founded in 2017 by Inceptus Medical as the incubator's second portfolio company. The company develops and commercializes the LOBO Vascular Occlusion System, a peripheral embolization platform featuring proprietary HD BRAID technology — a high-density, small-pore braid using wires less than 20 microns in diameter. The LOBO system is offered in four sizes (LOBO-3, LOBO-5, LOBO-7, LOBO-9) covering vessel diameters from 1.5mm to 9mm, and is complemented by the SENDERO Microcatheter and SENDERO MAX Delivery Catheter, purpose-built delivery devices optimized for the LOBO occluders. All products are FDA 510(k) cleared and target hospital-based interventional radiologists and vascular surgeons performing peripheral arterial embolization procedures across indications including PAVMs, bronchial, renal, splenic, GDA, and uterine artery embolization.

Okami generates revenue through per-unit hardware sales of its occluders and delivery catheters to hospitals under negotiated GPO or contract pricing, with documented per-case cost savings of $373–$2,041 versus detachable coils serving as the primary economic value proposition. The company distributes exclusively through a direct field sales organization organized under a VP of Marketing & Sales and a VP of Strategy, Finance & Commercial Operations, with no e-commerce or third-party channel. The platform is protected by at least ten granted US patents (covering device architecture, manufacturing, and delivery systems) and three registered trademarks (LOBO, SENDERO, HD BRAID).

The company has raised approximately $89.2 million across four funding rounds (2017–2025), with the most recent oversubscribed $45 million round in November 2025 led by Gilde Healthcare and joined by Vensana Capital and U.S. Venture Partners. Concurrent with this financing, Okami appointed Drew Hykes — former CEO of Inari Medical through its $5 billion Stryker acquisition — as President and CEO, and elevated Bill Hoffman, former Inari Medical CEO, to Chairman. The company operates exclusively in the United States with 11–50 employees and is currently generating clinical evidence through the ALPHA Registry, which plans to enroll up to 500 patients across 30 sites.

Name

Okami Medical

Legal name

Okami Medical, Inc.

Website

https://okamimedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Okami Medical develops and commercializes the LOBO Vascular Occlusion System and SENDERO delivery catheters, proprietary HD BRAID-based devices for peripheral vascular embolization sold to hospital-based interventional radiologists and vascular surgeons across the United States.

Ownership category

akta.pro rank

Product category

Peripheral Vascular Embolization Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industry

Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK)

Keywords

• Vascular embolization devices
• Peripheral vascular occlusion
• Interventional radiology devices
• Delivery microcatheters
• Vascular occluder systems

Headquarters

HQ city

Aliso Viejo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Hardware Sales: Okami Medical generates revenue through the sale of its proprietary medical devices — the LOBO Vascular Occlusion System (occluder devices in multiple sizes) and the SENDERO Delivery Catheter family. These are capital medical devices sold to hospitals and interventional radiology departments on a per-unit basis, typical of the medical device implant/devices sector. The company positions the LOBO as a cost-efficient alternative to detachable coils, saving $373-$2,041 per case vs. coils.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Core offering

Okami Medical develops, manufactures, and sells peripheral vascular embolization devices for interventional radiologists and vascular surgeons. Its primary products are the LOBO Vascular Occlusion System (occluders in four sizes covering vessels from 1.5mm to 9mm) built on proprietary HD BRAID technology, and the SENDERO family of purpose-built delivery catheters. Revenue is generated through the sale of these proprietary medical devices to hospitals and interventional radiology departments on a per-unit basis, with devices positioned as a single-device alternative to detachable coils and vascular plugs.

Product overview

Okami Medical offers a unified vascular embolization platform consisting of the LOBO Vascular Occlusion System and SENDERO Delivery Catheters. The LOBO system uses proprietary HD*BRAID technology for fast, single-device occlusion of peripheral arteries, available in four sizes (LOBO-3, LOBO-5, LOBO-7, LOBO-9) covering vessel diameters from 1.5mm to 9mm. The SENDERO Microcatheter and SENDERO MAX are purpose-built delivery devices optimized specifically for the LOBO occluders, creating an integrated end-to-end solution for peripheral vascular embolization procedures.

Differentiator

Problem solved

Functional benefit

Brands

• LOBO: LOBO HD BRAID Vascular Occluder - A peripheral embolization device featuring proprietary HD BRAID technology for fast and complete occlusion of peripheral vessels.
• SENDERO
• SENDERO MAX

Products and services

• LOBO Vascular Occlusion System A peripheral vascular embolization device featuring proprietary HD BRAID technology that enables rapid and complete occlusion of peripheral arteries with a single device. Available in four sizes (LOBO-3, LOBO-5, LOBO-7, LOBO-9) covering vessel diameters from 1.5mm to 9mm, with a self-expanding, low-profile, microcatheter-compatible design for navigation through tortuous peripheral vessels and a single-click mechanical detachment handpiece. Indicated for obstructing or reducing the rate of blood flow in arteries of the peripheral vasculature.
• SENDERO Microcatheter A specialized delivery catheter optimized for use with LOBO-3 and LOBO-5 occluders, featuring hydrophilic coating, stainless steel braid, radiopaque marker band for trackability and precise placement, and a lubricious PTFE inner liner for low-friction delivery of interventional devices through tortuous peripheral vessels. Indicated for the peripheral vasculature for the infusion of diagnostic and therapeutic agents.
• SENDERO MAX Delivery Catheter An expanded delivery catheter designed for use with LOBO-7 and LOBO-9 occluders, providing optimal trackability and precise placement for larger peripheral vessel embolization procedures. Indicated for the peripheral vasculature for the infusion of diagnostic and therapeutic agents.

Quantifiable outcome

• Average 90-second occlusion time with single LOBO device across a wide range of cases (data on file)
• +4 more outcomes

Named customers7 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Inceptus Medical LLCcoreStrategic or Co-development PartnerInceptus Medical is the medical device incubator that created Okami Medical in 2017. Inceptus developed the core IP including HD BRAID technology and the LOBO system, licensing key patents (e.g., U.S. Patent No. 10,376,267) to Okami. The Inceptus team, including founder Bob Rosenbluth, has a track record of creating successful vascular device companies including Inari Medical, Sequent Medical, and MicroVention.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Penumbra: Penumbra is a leading interventional company with a peripheral embolization portfolio (e.g., detachable coils and the Ruby/POD system). It directly competes with Okami's LOBO in the same peripheral vascular occlusion procedures performed by interventional radiologists.
• Abbott: Abbott markets the Amplatzer Vascular Plug family, a direct alternative to LOBO for peripheral embolization. It competes head-to-head in many of the same peripheral vessel occlusion indications.
• Cook Medical: Cook Medical supplies a wide range of embolization coils and vascular occlusion devices used by interventional radiologists. It is a long-standing incumbent in the peripheral embolization space that Okami must displace account by account.

Broad incumbents

• Boston Scientific: Boston Scientific is a diversified interventional medtech incumbent with peripheral embolization offerings (e.g., Interlock and VortX coils). It targets the same hospital IR accounts as Okami but as part of a much broader device portfolio.
• Medtronic: Medtronic is a diversified cardiovascular and peripheral vascular incumbent with embolization and vascular occlusion products. It competes for the same IR/VS customers and procedure budgets, particularly via its embolization coil lines.
• Stryker: Stryker acquired Inari Medical in 2025, making it a major peripheral vascular incumbent with deep IR commercial reach and an explicit interest in peripheral embolization and vascular occlusion adjacencies.
• Terumo: Terumo acquired MicroVention and Sequent Medical (both co-founded by Okami founder Bob Rosenbluth). It is a global neurovascular and peripheral vascular incumbent and a credible strategic acquirer of HD BRAID-style technology.
• Johnson & Johnson (CERENOVUS / DePuy Synthes): Johnson & Johnson's CERENOVUS business sells peripheral and neurovascular embolization coils. It is a broad incumbent competitor for hospital IR accounts and peripheral embolization procedure share.

Emerging players

• Shape Memory Medical: Shape Memory Medical develops peripheral vascular embolization devices (e.g., the IMPEDE and IMPEDE-FX family). It is a smaller, niche competitor operating in the same peripheral embolization category with overlapping hospital IR customers.
• Sirtex Medical: Sirtex is an interventional oncology and embolization company with products targeting similar peripheral and hepatic embolization procedures. It is comparable as a niche specialist in catheter-delivered embolization therapy serving interventional radiology customers.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/okamimedical
• LinkedInlinkedin.com/company/okamimedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Okami Medical